Reviewing Fortress Biotech Inc. (FBIOP)’s and BeyondSpring Inc. (NASDAQ:BYSI)’s results

This is a contrast between Fortress Biotech Inc. (NASDAQ:FBIOP) and BeyondSpring Inc. (NASDAQ:BYSI) based on their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fortress Biotech Inc. 228.27M 0.54 69.68M -1.59 0.00
BeyondSpring Inc. N/A 0.00 56.85M -2.54 0.00

Table 1 highlights Fortress Biotech Inc. and BeyondSpring Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Fortress Biotech Inc. (NASDAQ:FBIOP) and BeyondSpring Inc. (NASDAQ:BYSI)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Fortress Biotech Inc. -30.53% 0% 0%
BeyondSpring Inc. 0.00% -219.5% -180.8%

Institutional and Insider Ownership

The shares of both Fortress Biotech Inc. and BeyondSpring Inc. are owned by institutional investors at 0% and 1.4% respectively.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Fortress Biotech Inc. -5.5% 3.75% -9.29% -24.55% 0% -27.03%
BeyondSpring Inc. -3.63% 28.06% 8.7% -16.54% -31% -19.63%

For the past year BeyondSpring Inc. has weaker performance than Fortress Biotech Inc.

Summary

Fortress Biotech Inc. beats BeyondSpring Inc. on 5 of the 9 factors.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.